Home
Sitemap
中文版
English
Drugs
Medical Devices
Consultation Services
Health Technology Assessment
International Cooperation
About Us
FAQ
Drugs
Home
FAQ
Drugs
All
Class
Technical Dossier Review of Drugs
New Drug Application (NDA)
Investigational New Drug Application(IND)
Application of Bridging Study Evaluation (BSE)
Active Pharmaceutical Ingredient (API)
Abbreviated New Drug Application (ANDA)
Drug Substance
CIRB
Botanical drug
Instruction Drugs
Postapproval Changes
Investigational New Drug Application(IND)
No.
Class
Title
231
Postapproval Changes
For post-approval site change of biologics, how to determine the shelf life for drug product manufactured at the new site?
232
Postapproval Changes
For biologics, what information should be provided for the change involving a drug product manufacturer/manufacturing facility?
233
Postapproval Changes
What is the consideration to use side-by-side comparison or historical data comparison for comparability studies of biologics?
Page
Page:
24/24
‧ Total:
233
19
|
20
|
21
|
22
|
23
|
24
Drugs
Medical Devices
Consultation Services
Health Technology Assessment
International Cooperation